secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K/A
Filed at:   2024-01-12T23:59:59+00:00
Accession:  0001140361-24-002118
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BC 9M 2023 revenue $86.3M, net income $18.8M; Gyre Therapeutics files financials for acquired entity
--------------------------------------------------------------------------------

- BC revenue $86.3M for 9M 2023 vs $77.4M in 9M 2022 (+11.5%); net income $18.8M vs $2.3M.
- Operating income $25.0M in 9M 2023, up from $7.2M in prior year period.
- Cash and CDs total $46.9M as of Sep 30, 2023; equity $83.8M.
- Business combination closed Oct 30, 2023; filing provides required historical financials of BC.
- Pro forma combined financials also filed as Exhibit 99.2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/0001140361-24-002118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/ef20018550_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-002118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer